Literature DB >> 1652145

Differential effects of anxiogenic central and peripheral benzodiazepine receptor ligands in tests of learning and memory.

P V Holmes1, R C Drugan.   

Abstract

Previous research has demonstrated that low doses of anxiogenic central benzodiazepine receptor (CBR) ligands, the beta-carbolines, improve performance in various learning and memory tests in animals if administered prior to training. The present experiments compared the effect of a beta-carboline (FG 7142) with that of a pharmacologically distinct anxiogenic compound, a peripheral benzodiazepine receptor (PBR) ligand, 4'-chlorodiazepam (Ro5-4864), in two tests of learning and memory in rats. As expected, FG 7142 significantly improved performance in a passive avoidance test. Ro5-4864 was without effect. In a shuttlebox escape test, Ro5-4864 significantly impaired performance while FG 7142 had no effect. The effect of Ro5-4864 was antagonized by the specific peripheral benzodiazepine receptor antagonist, PK 11195. These results indicate that the differential impact of CBR and PBR anxiogenic ligands on performance in aversively-motivated learning tests may be a reflection of their distinct pharmacologies.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1652145     DOI: 10.1007/bf02244187

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  40 in total

1.  Antagonism of flurazepam and other effects of Ro15-1788, PK8165 and Ro5-4864 on the GABA-A receptor complex in rat cuneate nucleus.

Authors:  M A Simmonds
Journal:  Eur J Pharmacol       Date:  1985-10-29       Impact factor: 4.432

Review 2.  Molecular mechanisms in the receptor action of benzodiazepines.

Authors:  E Costa; A Guidotti
Journal:  Annu Rev Pharmacol Toxicol       Date:  1979       Impact factor: 13.820

3.  Properties of [3H]diazepam binding sites on rat blood platelets.

Authors:  J K Wang; T Taniguchi; S Spector
Journal:  Life Sci       Date:  1980-11-17       Impact factor: 5.037

4.  Ro 5-4864: a potent benzodiazepine convulsant.

Authors:  B A Weissman; J Cott; S M Paul; P Skolnick
Journal:  Eur J Pharmacol       Date:  1983-05-20       Impact factor: 4.432

5.  A solid state device for measuring sensitivity to thermal pain.

Authors:  J M Walker; W C Dixon
Journal:  Physiol Behav       Date:  1983-03

6.  Phenylquinolines PK 8165 and PK 9084 allosterically modulate [35S]t-butylbicyclophosphorothionate binding to a chloride ionophore in rat brain via a novel Ro5 4864 binding site.

Authors:  K W Gee
Journal:  J Pharmacol Exp Ther       Date:  1987-03       Impact factor: 4.030

7.  The peripheral benzodiazepine receptor ligand Ro 5-4864 induces supraspinal convulsions in rabbits. Reversal by the central benzodiazepine antagonist Ro 15-1788.

Authors:  M Massotti; D Lucantoni
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

8.  Low and high doses of benzodiazepine receptor inverse agonists respectively improve and impair performance in passive avoidance but do not affect habituation.

Authors:  S E File; S Pellow
Journal:  Behav Brain Res       Date:  1988-09-01       Impact factor: 3.332

9.  Opposite effects of an agonist, RO5-4864, and an antagonist, PK 11195, of the peripheral type benzodiazepine binding sites on audiogenic seizures in DBA/2J mice.

Authors:  J Bénavidès; F Guilloux; D E Allam; A Uzan; J Mizoule; C Renault; M C Dubroeucq; C Guérémy; G Le Fur
Journal:  Life Sci       Date:  1984-06-25       Impact factor: 5.037

10.  Characterization of stress-induced alterations in [3H] Ro5-4864 binding to peripheral benzodiazepine receptors in rat heart and kidney.

Authors:  R C Drugan; A S Basile; J N Crawley; S M Paul; P Skolnick
Journal:  Pharmacol Biochem Behav       Date:  1988-08       Impact factor: 3.533

View more
  1 in total

1.  Ligand for translocator protein reverses pathology in a mouse model of Alzheimer's disease.

Authors:  Anna M Barron; Luis M Garcia-Segura; Donatella Caruso; Anusha Jayaraman; Joo-Won Lee; Roberto C Melcangi; Christian J Pike
Journal:  J Neurosci       Date:  2013-05-15       Impact factor: 6.167

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.